Trial Profile
Phase I Double-Blinded Comparison Study Using TXA127 and/or Neupogen to Increase Peripheral Blood Stem Cell (CD34+) Counts
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Angiotensin-1-7 (Primary)
- Indications Adult respiratory distress syndrome; Peripheral vascular disorders; Pulmonary arterial hypertension; Stem cell engraftment; Stroke; Thrombocytopenia
- Focus Adverse reactions
- Sponsors US Biotest Inc
- 01 Dec 2014 New trial record